Results for nevrotoksina translation from Slovenian to English

učinek sočasne uporabe različnih serotipov nevrotoksina botulina ni znan.
the effect of administering different botulinum neurotoxin serotypes concurrently is unknown.

ni zadostnih podatkov o uporabi botulinskega nevrotoksina tipa a pri nosečnicah.
there are no adequate data from the use of botulinum neurotoxin type a in pregnant women.

klinični učinek botulinskega nevrotoksina tipa a se lahko s ponavljajočim se injiciranjem poveča ali zmanjša.
the clinical effects of botulinum neurotoxin type a can increase or decrease by repeated injections.

mehanizem delovanja botulinskega nevrotoksina tipa a na holinergične živčne končiče poteka v treh zaporednih korakih:
the mechanism of action by which botulinum neurotoxin type a exerts its effects on cholinergic nerve terminals can be described by a three-step sequential process which includes the following steps:

predložitev rezultatov študije farmakodinamike, v kateri je širjenje nevrotoksina ovrednoteno glede na dva druga pripravka zdravila botox.
to submit the results of a pharmacodynamic study in which “ spread” of neurotoxin is quantified in comparison to two other botox preparations.

pojav disfagije se lahko pripiše širjenju farmakološkega učinka zdravila xeomin, ki je posledica širjenja nevrotoksina v mišice ezofagusa.
the occurrence of dysphagia is attributable to the spread of the pharmacological effect of xeomin as the result of the neurotoxin spread into the oesophageal musculature.

težka veriga botulinskega nevrotoksina tipa a se izjemno selektivno in z veliko afiniteto veže na receptorje, ki jih najdemo samo na holinergičnih končičih.
the heavy chain of the botulinum neurotoxin type a binds with an exceptionally high selectivity and affinity to receptors only found on cholinergic terminals.

po injiciranju botulinskega nevrotoksina tipa a redko lahko pride do anafilaktične reakcije (glejte poglavje 4. 8).
an anaphylactic reaction may occur rarely after injection of botulinum neurotoxin type a (see section 4.8).

po vstopu nevrotoksina lahka veriga specifično razcepi ciljni protein (snap 25), ki je nujen za sproščanje acetilholina.
after internalisation of the neurotoxin the light chain cleaves very specifically a target protein (snap 25) that is essential for the release of acetylcholine.

1 viala vsebuje 100 enot ld50 nevrotoksina bakterije clostridium botulinum tipa a (150 kd), brez beljakovin, ki tvorijo komplekse.
1 vial contains 100 ld50 units of clostridium botulinum neurotoxin type a (150kd), free of complexing proteins

proste molekule botulinskega nevrotoksina tipa a, ki se ne vežejo na receptorje na presinaptičnih holinergičnih živčnih končičih, bodo fagocitirane ali pinocitirane in razkrojene kot vsi drugi prosto cirkulirajoči proteini.
free circulating botulinum neurotoxin type a molecules which have not bound to presynaptic cholinergic nerve terminal receptors will be phagocytosed or pinocytosed and degraded like any other free circulating protein.

"ni bilo raziskano, ali je sekundarni neodziv zaradi razvoja protiteles pri zdravljenju z zdravilom xeomin manj pogost kot pri zdravljenju s klasičnimi pripravki, vsebujočimi kompleks nevrotoksina botulina tipa a.
lastly, the proposed spc for xeomin does not claim a potentially lower risk of development of antibodies with the product: “ it has not been investigated whether secondary non-response due to the development of antibodies is less frequent under xeomin therapy than under treatment with conventional preparations containing the botulinum neurotoxin type a complex.

klinična potrditev učinka nevrotoksina na mišico, v katero je injiciran: npr. z elektromiografskim pregledom v specializirani ustanovi analiza razlogov za odsotnost odziva, npr. slaba izolacija mišic, v katere naj bi bilo zdravilo injicirano, premajhen odmerek, slaba tehnika injiciranja, fiksna kontraktura, prešibek antagonist, morebiten nastanek protiteles ponovna ocena ustreznosti zdravljenja z botulinskim nevrotoksinom tipa a če se med prvim zdravljenjem niso pojavili neželeni učinki, je treba opraviti naslednji cikel zdravljenja pod naslednjimi pogoji:
analysis of the reason for non-response, e. g. poor isolation of the muscles intended to be injected, too low dose, poor injection technique, fixed contracture, too weak antagonist, possible development of antibodies